Viking Global Investors
BHVN

Viking Global Investors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Viking Global Investors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-966,139
Closed -$115M – 106
2022
Q1 		$115M Buy
966,139
+617,356
+177% +$77M 0.46% 58
2021
Q4 		$48.1M Buy
+348,783
New +$44.4M 0.14% 87

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors's BHVN Position: Q2 2022 in Review

Viking Global Investors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 966,139 shares — an estimated $115M sold.

Viking Global Investors first reported a position in BHVN in Q4 2021 and held it in 2 quarters. The position peaked at $115M in Q1 2022. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Viking Global Investors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Viking Global Investors sold 966,139 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $115M.
  • Viking Global Investors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 2 quarters.
  • Viking Global Investors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $115M in Q1 2022.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Viking Global Investors's 13F filing for Q2 2022, filed 15 Aug 2022.